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Abstract
Background: DNMT3B polymorphisms are associated with the susceptibility of lung cancer. DNMT3B −2437T>A is a
novel polymorphism, and its influence on the risk of lung cancer in Chinese was investigated in this study. In addition,
effect of DNMT3B −149C>T polymorphism on lung cancer was also explored.
Methods: Genotyping in subjects were performed by PCR-RFLP. Haplotype frequencies were estimated by estimating
haplotype software. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by unconditional
logistic regression analysis.
Results: Neither of the two polymorphisms was correlated with lung cancer (−149C>T: CT+TT vs CC: OR = 0.78, 95%CI,
0.57 to 1.05, P = 0.361; −2437T>A: AT+AA vs TT: OR = 0.99, 95%CI, 0.74 to 1.33, P = 0.168). In stratification
analysis, T-allele carrier genotype of −149C>T polymorphism resulted in a reduced lung cancer risk at stage II,
compared with CC (OR = 0.46, 95%CI, 0.28 to 0.77, P = 0.023). In haplotype analysis, when −149C/−2437T was
used as reference, the other combined genotypes of the two polymorphisms had no significant effect on
lung cancer risk (P > 0.05).
Conclusions: The two DNMT3B polymorphisms are not correlated with lung cancer risk among Chinese
population nor the haplotype of them.
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Background
Lung cancer is the major reason for death and is more
frequent in men worldwide [1]. Although lung cancer
incidence has a decreasing trend in several high-income
countries due to a decreased smoking prevalence, the
trend in global is increasing [2]. Reportedly, approxi-
mately 1,590,000 individuals have died from lung cancer
in the world [3]. Moreover, the 5-year survival rate of
lung cancer is low, which is about 15% of the newly
diagnosed cases [4].
Accumulating evidence has demonstrated that genetic
variations are associated with cancer risks, and several of
them are proposed as biomarkers for cancer diagnosis
[5, 6]. One hallmark of lung cancer is the alteration in
DNA methylation patterns, and methylated CpG islands
are suggested as biomarkers for diagnosis and detection
of early cancer [7, 8]. DNA methylation mediated by
DNA methyltransferases, such as DNMT3A and
DNMT3B, has been identified as an important epigenetic
mechanism for regulation of chromosomal stability [9].
DNMT3A and DNMT3B action as two de novo methyl-
transferases to target the un-methylated CpG sites on
gene promoter, thus build a new methylation pattern [10].
These two DNMTs contribute to reprogramming of the
epigenome in many cancer types such as lung cancer [11].
The DNMT3B gene is characterized by highly poly-
morphic, and 345 polymorphisms of this gene have been
detected [9]. Reportedly, DNMT3B −149C>T polymorph-
ism is highly related to the increased promoter activity [12].
A previous case-control study has demonstrated the hy-
pothesis that T allele in DNMT3B −149C>T polymorphism
is tightly related to the increased risk of lung cancer among
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non-Hispanic whites [13]. However, the sample size is
relatively small (319 patients and 340 controls). More-
over, different populations could generate different re-
sults in other cancers [14, 15], thus we conducted
this study among the Chinese population. Currently,
other DNMT3B polymorphisms, such as −579G>T
and −283T>C, are investigated to ascertain their in-
fluences on lung cancer [16, 17]. It is hypothesized
that haplotypes of DNMT3B polymorphisms may regu-
late the susceptibility to lung cancer, and among the
three DNMT3B polymorphisms (−149C>T, −579G>T,
and −283T>C), the haplotype −283T/−579G is reported
to have a decreased effect on the risk of lung adenocar-
cinoma [16].
Herein, we conducted this case-control study recruiting
a total of 1286 Chinese participants (684 cases and
602 controls), to explore the effects of DNMT3B −149C>T
polymorphism on the susceptibility of lung cancer in
Chinese population. In addition, we identified a
novel DNMT3B polymorphism, −2437T>A, and also
explored its relationship with lung cancer risk. Fur-
thermore, we investigated influence from haplotypes
of the two DNMT3B polymorphisms on the risk of lung
cancer, aiming to provide novel insights into mecha-




A cohort of 1286 subjects (lung cases: 684; healthy con-
trol: 602) were enrolled at the Third Hospital of Harbin
Medical University. Patients were hospitalized from
September 2009 to March 2011 and confirmed to suffer
from primary lung cancer by pathological diagnosis with-
out any hereditary disease. Tumor stages were examined
based on the tumor-node-metastasis (TNM) classification
[18]. Staging examination was performed such as chest X-
ray; bronchofiberscopy; and chest, abdomen, and head CT
scan and bone scan. Those who had smoked five cigarettes
1 day for two or more than 2 years were considered as
“smokers.”
Genotyping procedures
A volume of 5-mL veinal blood was obtained from each
patient and kept at 4 °C after natrium citricum anticoagula-
tion. Genomic DNA was extracted from peripheral blood
lymphocytes within 1 week by the proteinase K digestion-
saturated sodium chloride salting out method [19]. Then
the DNA purity was evaluated by NanoDrop spectropho-
tometer, through calculating 260/280 nm ratio [20]. PCR-
RFLP (polymerase chain reaction-restriction fragment
length polymorphism) method was used to perform the
genotyping analysis of the two DNMT3B polymorphisms,
according to the protocol of Lee et al. [16]. In brief, PCR
reactions were carried out in a 20-μl reaction system, con-
sisting of 100 ng genomic DNA, 2 μl 10× buffer (20 mmol/
L MgCl2), 160 μmol/L dNTPs, 200 nmol/L of each primer,
and 2 U of Tag polymerase (Promega). Primers for the
DNMT3B −149C>T polymorphism were C74468A, 5′-
GCCATATCAGTGAACCTTTAGAGAC-3′; G74582A,
5′-GGGG AGCACAATTTCCCTTC-3′; and for the
−2437T>A polymorphism were C72555A, 5′-GGAACTG-
GAACTCAAGGCAAG-3′; T72687A, 5′- ACATGAAT-
TATTGCTTATCG-3′. For −149C>T polymorphism, the
third base in 3′ end of the forward primer was transferred
from A to G, to create a Hinf I restrictive site; and for
−2437T>A, the mutated base was “A” in the 3′ end of the
forward primer, to generate a Tag I restrictive site. The
PCR condition was initial denaturation at 94 °C for
5 min and then 35 cycles of the following procedures:
45 s at 94 °C, then 45 s at 58 °C for −149C>T and 45 s
at 61.3 °C for −2437T>A, 45 s at 72 °C, a final elong-
ation at 72 °C for 10 min.
The 286 bp PCR product of −149C>T was digested
with 10 U Hinf I at 37 °C for 16 h, resolved on 4% acryl-
amide gel (8 μg/mL), and stained with ethidium bromide
(EB) for visualization under UV light. Then polymorph-
ism of DNMT3B −149C>T was genotyped basing on the
band numbers: the CC genotype generates only one
band (the entire 286 bp fragment), the TT produces two
bands (245 and 23 bp), and heterozygote CT genotype
yields three bands (286, 245, and 23 bp).
The 355 bp PCR product of −2437T>A was digested
with 10 U Tag I at 37 °C for 16 h, resolved on 4% acryl-
amide gel, and stained with EB for visualization under
UV light. The TT genotype produces one band (355 bp),
AA genotype generates two bands (225 and 130 bp), and
heterozygote TA genotype yields three bands (355, 225,
and 130 bp).
For quality control, 10% of the individuals were ran-
domly extracted to repeat the genotyping analysis. The
genotyping results were 100% concordant. Additionally,
three random PCR-amplified DNA samples for each
genotype of the two polymorphisms were put through
DNA sequencing, respectively, to determine the reliabil-
ity of genotyping results, and the results were also 100%
concordant.
Statistical analyses
Differences in continuous variables are compared be-
tween control and lung cancer cases using the χ2-test,
such as allele frequency and genotype frequency distribu-
tion. Hardy-Weinberg equilibrium (HWE) was tested for
genotype distributions of the control subjects [21]. Haplo-
type frequencies were estimated by the estimating haplotype
software (http://linkage.rockefeller.edu/ott/eh.htm) [22].
The adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) by sex and age were determined with
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the unconditional logistic regression analysis. A P
value <0.05 indicates the statistical significance. Sub-
group analyses stratified by pathological type, TNM
stage, and smoke status were performed. All the stat-
istical analyses were performed by SPSS software
(Chicago, IL, USA).
Results
Characteristics of subjects in the study
Main characteristics of the subjects are listed in Table 1.
All patients have not received any anticancer therapy
nor had the history of occupational exposure to car-
cinogenic factors. Tumor types were determined ac-
cording to lung tumor tissue typing classification, and
there were 221 (32.26%) squamous carcinoma cases,
257 (37.54%) adenocarcinoma cases, 142 (20.83%) small
cell carcinoma, and 64 (9.37%) other carcinoma cases.
A total of 239 (34.9%) patients were in stage I, 181
(26.5%) were in stage II, 235 (34.4%) were in stage III,
and 29 (4.2%) were in stage IV. There were no obvious
differences on the subject number distributions be-
tween the two kinds of samples with regard to gender
and mean age. However, lung cancer cases had a signifi-
cant higher frequency of smokers than controls (66.9 vs
44.6%), suggesting smoking was a causative factor for
lung cancer risk.
Genotype frequency and associations between
DNMT3B −149C>T and −2437T>A polymorphisms and
risk of lung cancer
Genotype distributions of the two polymorphisms are
shown in Table 2. For DNMT3B −149C>T polymorph-
ism, when CC genotype was used as reference, the T-
allele carrier genotypes (CT+TT) did not show any pro-
nounced correlations with risk of lung cancer (OR =
0.78, 95% CI, 0.57 to 1.05, P = 0.361). Likewise, signifi-
cant differences were detected in neither TT genotype
(OR = 0.90, 95% CI, 0.62 to 2.37, P = 0.406) nor CT geno-
type (OR = 1.42, 95% CI, 0.34 to 1.53, P = 0.541), compared
with CC. For DNMT3B −2437T>A polymorphism, when
TT genotype was used as reference, the A-allele carrier
genotypes (AT+AA) were not remarkably related to lung
cancer risk (OR = 0.99, 95% CI, 0.74 to 1.33, P = 0.168).
No significant differences were detected in AA geno-
type (OR = 1.22, 95% CI, 0.58 to 1.35, P = 0.215) or TA
genotype (OR = 1.00, 95% CI, 0.42 to 1.67, P = 0.308),
compared with TT genotype. In control subjects, the
Table 1 Baseline characteristics of subjects in lung cancer








Male 498 (72.8) 400 (66.5) 0.703 0.402
Female 186 (28.2) 202 (33.5)
Age (x ± s) 56.1 ± 11.3 57.1 ± 10.0 1.306 0.192
<60 408 (59.7) 328 (54.5) 2.006 0.157
≥60 276 (40.3) 274 (45.5)
Smoking status
Smokers 458 (66.9) 268 (44.6) 37.461 0.001
Non-smokers 226 (33.1) 334 (55.4)
Pathological type
SCC 221 (32.3) –
AC 257 (37.6) –
ASC 64 (9.4) –
SCLC 142 (20.8) –
TNM staging
I 239 (34.9) –
II 181 (26.5) –
III 235 (34.4) –
IV 29 (4.2) –
T2437A allele
T 559 (69.2) 497 (70.6) 0.357 0.550
A 249 (30.8) 207 (29.4)
C149T
C 619 (76.6) 559 (79.4) 1.707 0.191
A 189 (23.4) 145 (20.6)
SCC squamous cell carcinoma, AC adenomatous carcinoma, ASC
adenosquamous carcinomas, SCLC small cell lung cancer,
TNM tumor-node-metastasis
Table 2 Genotype distribution of DNMT3B −149C>T and −2437T>A
polymorphisms and their associations with lung cancer risk
Genotype No. of cases (%) No. of controlsa (%) ORb (95% CI) P value
−149C>T
TT 35 (5.1) 38 (6.3) 0.90
(0.62 2.37)
0.406
CT 249 (36.4) 172 (28.6) 1.42
(0.34 1.53)
0.541
CC 400 (58.5) 392 (65.1) Reference
T-allele
carriers




AA 76 (11.1) 56 (9.3) 1.22
(0.58 1.35)
0.215
TA 269 (39.4) 241 (40.1) 1.00 (0.42
1.67)
0.308
TT 339 (49.5) 304 (50.6) Reference
A-allele
carriers
345 (50.5) 297 (49.4) 0.99
(0.74, 1.33)
0.167
No. number of cases or controls, OR odds ratio, CI confidence interval
aThe observed genotype distribution in controls was in accordance with the
Hardy-Weinberg equilibrium (P = 0.153 for DNMT3B −149C>T and P = 0.187 for
DNMT3B −2437T>A)
bAdjusted for age and sex in a logistic regression model
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genotype frequency was in accordance with HWE
expectation (P > 0.05).
Subgroup analysis
Subgroup analysis stratified by pathological type indi-
cated that there were no significant associations between
any of the two DNMT3B polymorphisms and the risk of
any lung cancer type (Table 3).
With regard to TNM staging, only the CT+TT ge-
notypes of −149C>T polymorphism showed a signifi-
cant reduced lung cancer risk at the II stage, compared
with the genotype of CC (OR = 0.46, 95% CI, 0.28 to 0.77,
P = 0.023), while −2437T>A polymorphism was not related
to risk of lung cancer risk at any stage (Table 4).
When stratified by smoke status, we found that compared
with CC genotype of DNMT3B −149C>T polymorphism,
none of the TT (smoker group: OR = 0.81, 95%CI, 0.84 to
2.35, P = 0.571; non-smoker group: OR = 1.59, 95% CI, 0.37
to 1.94, P = 0.371), CT (smoker group: OR = 0.74, 95% CI,
0.45 to 1.83, P= 0.469; non-smoker group: OR = 0.69,
95%CI, 0.24 to 1.64, P = 0.108), and TT+CT (smoker group:
OR = 0.76, 95% CI, 0.52 to 1.17, P = 0.274; non-smoker
group: OR = 0.77, 95% CI, 0.49 to 1.25, P = 0.251) indicated
a significant difference in neither smoker group nor non-
smoker group (Table 5). The OR values were newly the
same in each comparison of the smoker group and the
non-smoker group. For −2437T>A polymorphism, similar
results were observed, and there were no significant differ-
ences between the allelic genotypes (AA, TA, and AA+TA)
and TT genotype in smoker group or non-smoker
group (P > 0.05, Table 5). Interestingly, we found that
ORs of AA, TA, and AA+TA in smoker group were slightly
higher than non-smokers (AA: 1.53 vs 0.71; TA: 1.78 vs
1.07; and AA+TA: 1.72 vs 1.00), which suggested that
these genotypes might be more frequent in smokers than
non-smokers.
Haplotype analysis of the two polymorphisms
Four combined genotypes (149C/2437T, 149C/2437A,
149T/2437T, and 149T/2437A) were investigated be-
tween the two polymorphisms. When the genotypes
of −149C/−2437T were used as the reference group, no
remarkable correlation was detected between the other
combined genotypes and risk of lung cancer (P > 0.05,
Table 6).
Discussion
The present study investigated the association between
two DNMT3B polymorphisms, −149C>T and −2437T>A,
and lung cancer risk. As a result, neither of the two poly-
morphisms was at a significantly increased or decreased
risk of lung cancer, when the wild genotypes (CC for
149C>T and TT for −2437T>A) were used as the refer-
ence groups. In the stratification analysis, T-allele carrier
genotype of −149C>T polymorphism was closely related
to decreased lung cancer risk at stage II, compared with
the wild genotype (CC).
DNA methylation promotes the progression of cancer
cells, and DNMT3B plays significant roles in hyperme-
thylation and hypomethylation of genomic DNA [23].
Increased DNMT3B expression has been discovered in
lung cancer [24]. DNMT3B −149C>T polymorphism is
known to enhance the gene’s promoter activity, and a
previous study has demonstrated that T-allele carrier ge-
notypes, especially CT genotype, are significantly related
to increased risk of lung cancer [13]. The possible ex-
planation is the increased promoter activity of DNMT3B
by this C to T transition might up-regulate genes that
involve in regulation of methylation of some tumor
Table 3 Subgroup analysis stratified by pathological type
Genotype Pathological type
SCC ORa (95%CI) AC ORa (95%CI) ASC ORa (95%CI) SCLC ORa (95%CI)
−149C>T
TT 19 (8.5) 0.54 (0.31 1.56) 15 (5.8) 0.23 (0.33 2.01) 6 (9.8) 0.17 (0.54 1.98) 7 (4.8) 0.24 (0.31 2.12)
CT 63 (28.7) 0.76 (0.25 1.81) 81 (31.7) 0.81 (0.77 1.67) 22 (34.1) 0.42 (0.34 1.63) 37 (25.8) 0.58 (0.22 1.37)
CC 139 (62.8) Reference 161 (62.5) Reference 36 (56.1) Reference 99 (69.4) Reference
CT+TT 82 (37.2) 0.82 (0.53 1.27) 96 (37.5) 0.90 (0.59 1.39) 68 (.43.9) 0.55 (0.26 1.15) 44 (30.6) 0.63 (0.35 1.44)
−2437T>A
AA 31 (14.0) 0.57 (1.21 2.14) 11 (4.2) 0.45 (0.72 1.51) 6 (9.8) 0.26 (1.32 2.31) 14 (9.7) 0.37 (0.87 1.92)
TA 79 (35.6) 0.85 (0.58 1.67) 122 (47.5) 0.89 (0.22 1.21) 22 (34.1) 0.76 (0.28 1.64) 55 (38.7) 0.88 (0.64 1.55)
TT 111 (50.4) Reference 124 (48.3) Reference 36 (56.1) Reference 73 (51.6) Reference
TA+AA 110 (49.6) 0.99 (0.65 1.52) 133 (51.7) 1.08 (0.71 1.64) 68 (43.9) 0.83 (0.43 1.61) 69 (48.4) 0.95 (0.56 1.64)
SCC squamous cell carcinoma, AC adenomatous carcinoma, ASC adenosquamous carcinomas, SCLC small cell lung cancer, TNM tumor-node-metastasis, OR odds
ratio, CI confidence interval
aAdjusted for age and sex in a logistic regression model
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suppressor genes [13]. Unfortunately, our results were
inconsistent with this finding, and we did not detect any
association. The different results may be due to different
ethnic populations. Our study was conducted among
Chinese population, while Shen’s is among the non-
Hispanic whites. However, we enrolled more individuals
in the present study and performed subgroup analysis
stratified by lung cancer types and different tumor stages
as well as smoke status. Notably, It is the first discovery
that in stage II, T-allele carrier genotypes (CT and TT)
of −149C>T polymorphism were highly related to the re-
duced risk of lung cancer. The plausible reason might be
that gene expressions are different at different stages.
For instance, CDH13, RASSF1A, and APC are identified
as DNA methylation markers at stage I in non-small cell
lung cancer (NSCLC), and methylation of these genes in
the prompter region are associated with early recurrence
[25], while methylation of TFPI2 is mainly discovered in
advanced stage (stage III) of NSCLC [26]. In addition, al-
though methylation of several genes, such as RARβ,
TIMP-3, p16INK4a, DAPK, p14ARF, and GSTP1, are fre-
quently occurred in NSCLC, correlations between
methylation changes of these genes in NSCLC tumors
and the clinical data are different at different stages
(stages I to III) [27]. Our findings indicated that
DNMT3B −149C>T polymorphism might not be used as
the prognostic marker for lung cancer, especially in
Chinese population.
Several studies have reported the regulation or coord-
ination of DNMT3B by other genes. For instance, it is
common in cancer that the cell cycle-related genes, such
as p14ARF and p16INK4a, are inactivated. One major form
of the epigenetic inactivation of p14ARF and p16INK4a is
hypermethylation of CpG islands, and expressions of
these two genes are tightly associated with increased ex-
pression of DNMT3B [28]. The gene UHRF1, which
encodes a subfamily of RING-finger type E3 ubiquitin li-
gases, has an important role in DNA methylation main-
tenance [29]. In NSCLC, it is demonstrated that UHRF1
controls cell cycle through silencing of tumor suppressor
genes, and DNMT3B is also up-regulated in UHRF1
knockdown clones [30]. These collectively suggest that
DNMT3B’s role in lung cancer development might re-
quire involvement of other genes’ regulations. This pro-
vides a hint that in stage II, several potential suppressor
genes might express and exert an inhibitory role on
DNMT3B expression, despite the elevated prompter ac-
tivity. However, this hypothesis needs to be further
validated.
−2437T>A is a novel DNMT3B polymorphism that
has never been reported before. In the present study, like
−149C>T polymorphism, we did not find any association
between A-allele carrier genotypes (AT+TT) and lung
cancer risk, when CC was used as the reference group.
Stratification analysis also indicated that there was no
significant association. These findings suggest that al-
though this polymorphism is novel, it might not influ-
ence the expression of DNMT3B, or there are more
complicated mechanisms on the regulations of DNMT3B
when this T to A transition was emerged.
To investigate associations between the combined in-
fluence of these two polymorphisms and lung cancer
risk, the haplotype analysis was conducted and the result
indicated that when −149C/−2437T was used as the ref-
erence, the other combined genotypes of the two poly-
morphisms were not significantly related to increased or
decreased risk of lung cancer (P > 0.05). Nevertheless,
other studies investigating haplotype in other DNMT3B
polymorphisms reveal that −579G>T and −283T>C is a
haplotype that could affect the DNMT3B’s expression,
and the combined genotype −283T/−579G achieved a
reduced risk of adenocarcinoma, in comparison with
Table 4 Subgroup analysis stratified by different stages
Genotype TNM staging
Stage I ORa (95% CI) Stage II ORa (95%CI) Stage III ORa (95% CI) Stage IV ORa (95% CI)
−149C>T
TT 23 (9.8) 0.57 (0.32 1.78) 4 (2.2) 0.23 (0.29 1.57) 12 (5.0) 0.32 (0.31 1.58) 4 (13.3) 0.75 (0.31 1.28)
CT 78 (32.5) 0.92 (0.54 1.52) 41 (22.5) 0.38 (0.42 1.81) 68 (28.9) 0.65 (0.38 1.85) 10 (33.3) 1.02 (0.82 2.54)
CC 138 (57.7) Reference 136 (75.3) Reference 155 (66.1) Reference 15 (53.3) Reference
CT+TT 101 (42.3) 1.03 (0.68 1.55) 45 (24.7) 0.46 (0.28 0.77) 80 (32.9) 0.72 (0.47 1.10) 14 (46.6) 1.23 (0.44 3.46)
−2437T>A
AA 20 (8.1) 0.32 (0.28 1.35) 21 (11.8) 0.45 (0.28 2.51) 20 (8.3) 0.84 (0.81 1.95) 4 (13.3) 1.32 (0.82 1.69)
TA 91 (38.2) 0.72 (0.82 1.96) 66 (36.6) 0.78 (0.84 1.92) 101 (43.0) 0.97 (0.58 1.92) 15 (53.3) 1.56 (0.78 3.51)
TT 128 (53.7) Reference 93 (51.6) Reference 114 (48.7) Reference 10 (33.3) Reference
TA+AA 111 (46.3) 0.85 (0.57 1.27) 87 (48.4) 0.92 (0.59 1.44) 121 (51.3) 1.03 (0.69 1.55) 19 (66.6) 1.96 (0.66 5.84)
OR odds ratio, CI confidence interval
aAdjusted for age and sex in a logistic regression model
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−283C/−579T [16]. However, results might be different
in different lung cancer types. The present study indi-
cated that the haplotype −149C>T and −2437T>A was
not pronouncedly correlated with risk of lung cancer,
suggesting the two polymorphisms could not be consid-
ered as a haplotype, during the progression of lung
cancer.
The main limitation in the present study was that the
control samples were hospital-based, which might cause
selection bias. However, relevant data were adjusted by
sex and age to reduce influences from such confounding
factors and provide a reliable result. Additionally, inter-
actions of DNMT3B and other genes were not investi-
gated, which might affect the results. Nevertheless, our
findings are of great value to provide a novel insight into
effects of DNMT3B polymorphisms on risk of lung can-
cer among Chinese population.
Conclusions
In conclusion, two DNMT3B polymorphisms, −149C>T
and −2437T>A, are not related to lung cancer risk
among Chinese population nor the haplotype of them.
However, more studies with larger samples are required
to confirm our findings.
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Table 6 Association of DNMT3B −C149T and −T2437A
haplotype with the risk of lung cancer
Haplotype No. of controls (%) No. of cases (%) ORa (95%CI) P value
149C/
2437T
428 (53.0) 295 (56.0) Reference
149C/
2437A










58 (7.2) 43 (6.1) 0.80 (0.53,
1.22)
0.573
No. number of cases or controls, OR odds ratio, CI confidence interval
aAdjusted for age and sex in a logistic regression model
Table 5 Subgroup analysis stratified by smoke status
Genotype No. of cases (%) No. of controls (%) ORa (95% CI) P value
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0.571
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TT 19 (8.5) 16 (4.9) 1.59
(0.37 1.94)
0.371
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(0.24 1.64)
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(0.35 1.67)
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TT 138 (10.2) 139 (11.7) Reference





AA 35 (47.9) 29 (47.8) 0.71
(0.34 1.68)
0.376
TA 204 (44.4) 111 (41.5) 1.07
(0.32 1.85)
0.723
TT 219 (7.7) 128 (10.7) Reference
TA+AA 239 (92.3) 140 (89.3) 1.00
(0.64 1.59)
0.504
OR odds ratio, CI confidence interval
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